Role of vinpocetine in prevention of cognitive disorders in patients with arterial hypertension Review article
Article Sidebar
Published:
Dec 31, 2014
Keywords:
arterial hypertension, cognitive impairment, vinpocetine, Alzheimer’s disease, vascular dementia
Main Article Content
Abstract
Dementia is an increasingly common problem affecting Polish society. Both epidemiological and prospective studies demonstrated that long-standing hypertension can lead to impaired cognitive function and development of symptoms of dementia. Based on previous research we can suppose that effective antihypertensive therapy significantly reduces the risk of these changes in patients with hypertension. At the same time it should be emphasized that the cognitive impairment that coexists with hypertension can significantly impair cooperation with the patient, leading to ineffective antihypertensive therapy and increasing the risk of many complications. Vinpocetine can play an important role in the treatment of such a patient, resulting in improvement in cognitive function.
Article Details
How to Cite
Barylski , M., & Rosołowska, A. (2014). Role of vinpocetine in prevention of cognitive disorders in patients with arterial hypertension. Medycyna Faktow (J EBM), 7(4(25), 58-66. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2338
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Johnston S.V., O’Meara E.S., Manolio T.A. et al.: Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. Ann. Intern. Med. 2004; 140: 237-247.
2. Kilander L., Nyman H., Boberg M. et al.: Hypertension is related to cognitive impairment: a 20-year follow-up study of 999 men. Hypertension 1998; 31: 780-786.
3. Skoog I., Lernfelt B., Landahl S.: Fitteen-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
4. Elias M.E., Wolf P.A., D’Agostino R.B.: Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am. J. Epidemiol. 1993; 138: 353-364.
5. Tzourio C., Dufouil C., Ducimetiere P. et al.: Cognitive decline in individuals with high blood pressure. Neurology 1999; 53: 1948-1952.
6. Launer L.J., Masaki K., Petrovitch H. i wsp.: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu – Asia Aging Study. JAMA 2004; 292: 2237-2242.
7. Elias P.K., Elias M.F., Robbins M.A. et al.: Blood pressure-related cognitive decline: does age make a difference? Hypertension 2004; 44: 631-636.
8. Suhr J.A., Stewart J.C., France C.R.: The relationship between blood pressure and cognitive performance in the Third National Health and Nutrition Examination Survery (NHANES III). Psychosom. Med. 2004; 66: 291-297.
9. Kuo H.K., Yen C.J., Chang C.H. et al.: Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005; 4(6): 371-380.
10. Bellew K.M., Pigeon J.G., Stang P.E. et al.: Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Dis. Assoc. Disord. 2004; 18(4): 208-213.
11. Launer L.J., Masaki K., Petrovitch H. et al.: The association between midlife blood pressure levels and late-life cognitive function. JAMA 1995; 274: 1846-1851.
12. Launer L.J., Ross G.W., Petrovitch H. et al.: Midlife blood pressure levels and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2000; 21: 49-55.
13. Jennings J.R.: Autoregulation of blood pressure and thought: preliminary results of an application of brain amaging to psychosomatic medicine. Psychosom. Med. 2003; 65: 384-395.
14. Mulvany M.J.: Small aorty remodeling and significance in the development of hypertension. New Physiol. Sci. 2002; 17: 105-109.
15. Manolio T.A., Olson J., Longstreth W.T.: Nadciśnienie tętnicze a funkcje poznawcze: patofizjologiczny wpływ nadciśnienia tętniczego na mózg. Medycyna po Dyplomie 2004; 13(15): 88-98.
16. van Dijk W.J., Breteler M.M.B., Schmidt R. et al.; CASCADE Consortium: The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004; 44: 625-630.
17. Majeski E.I., Widener C.E., Basile J.: Hypertension and dementia: does blood pressure control favorably affect cognition? Curr. Hypertens. Rep. 2004; 6: 357-362.
18. Di Bari M., Pahor M., Franse L.V.: Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in elderly program (SHEP) trial. Am. J. Epidemiol. 2001; 153: 72-78.
19. Forette F., Seux M.I., Staessen J.A.: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch. Intern. Med. 2002; 162: 2046-2052.
20. Lithell H., Hansson L., Skoog I. et al.: The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 2004; 22: 1605-1612.
21. Lithell H., Hansson L., Skoog I.: The Study on COgnition and Prognosis in the Elderly (SCOPE); principal results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21: 875-886.
22. Feigin V., Ratnasabapathy Y., Anderson C.: Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J. Neurol. Sci. 2005; 229-230: 151-155.
23. McGuinness B., Todd S., Passmore P.: The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst. Rev. 2006; 2, CD004034.
24. Birkenhäger W.H., Staessen J.A.: Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog. Cardiovascular Dis. 2006; 49: 1-10.
25. Birns J., Morris R., Donaldson N. et al.: The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J. Hypertens. 2006; 24: 1907-1914.
26. Guo Z., Fratiglioni L., Zhu L. et al.: Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch. Neurol. 1999; 56: 991-996.
27. Hagstrom B., Mattsson B., Rost I.M. et al.: What happened to the prescriptions? A single, short, standardized telephone call may increase compliance. Fam. Pract. 2004; 21: 46-50.
28. Grodzicki T., Gryglewski R., Tomasik T. et al.: Zasady postępowania w nadciśnieniu tętniczym w wieku podeszłym. Wytyczne Kolegium Lekarzy Rodzinnych w Polsce, Polskiego Towarzystwa Nadciśnienia Tętniczego, Polskiego Towarzystwa Gerontologicznego. Gerontol. Pol. 2012; 20(4): 119-147.
29. Manconi E., Binaghi F., Pitzus F.: A double-blind clinical trial of vinpocetine in the treatment of cerebral insuficiency of vascular and degenerative origin. Curr. Ther. Res. 1986; 40: 702-712.
30. Reisberg B., Ferris S.H., Shulman E. et al.: Longitudinal course on normal ageing and progressive dementia of Alzheimer’s type: a prospective study of 106 subject over a 3,6 year mean interval. Prog. Neuro-Psychopharmacol. Psychiatry 1986; 10: 571-578.
31. Reisberg B., Ferris S.H., de Leon M.J. et al.: Stage specific behavioral cognitive, and in vivo changes in community residing subjects with age associated memory impairment and primary degenerative dementia of Alzheimer type. Drug Develop. Res. 1988; 15: 101-114.
32. Petersen R.C., Doody R., Kurz A. et al.: Current concepts in mild cognitive impairment. Arch. Neurol. 2001; 58: 1985-1992.
33. Petersen R.C., Smith G.E., Waring S.C. et al.: Mild cognitive impairment: clinical characterization an outcome. Arch. Neurol. 1999; 56: 303-308.
34. Winblad B., Palmer K., Kipivelto M. et al.: Mild cognitive impairment – beyond controversies, towards a consensus: report of International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004; 256: 240-246.
35. Mitchell A.J., Shiri Feshki M.: Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatr. Scand. 2009; 119: 252-265.
36. Krasuski J.S., Alexander G.E., Horwitz B.: Volumes of medial temporal lobe structures in patiens with Alzheimer’s disease and mild cognitive impairment. Biol. Psychiatry 1998; 43: 60-68.
37. Callahan M., Hendrie H.C., Tierny W.M.: Documentation and evaluation of cognitive impairment in elderly primary care patiens. Ann. Intern. Med. 1995; 122: 422-429.
38. Gabryelewicz T., Styczyńska M., Łuczywek E. et al.: The rate conversion of mild cognitive impairment to dementia: predictive role of depression. Int. J. Geriatr. Psychiatry 2007; 22: 563-567.
39. Jack C.R., Petersen R.C., Xu Y. Warring S.C. et al.: Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997; 49: 786-794.
40. Nicholson C.D.: Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990; 101: 147-159.
41. Bönöczk P., Gulyás B., Adam-Vizi V. et al.: Role of sodium chanel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 2000; 3: 245-254.
42. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. The Cochrane Database of Systematic Reviews 2003, Issue 1.
43. Jacobs J.D., Bernhard M.R., Delgado A. et al.: Screening for organic mental syndromes in the medically ill. Ann. Intern. Med. 1977; 86: 40-48.
2. Kilander L., Nyman H., Boberg M. et al.: Hypertension is related to cognitive impairment: a 20-year follow-up study of 999 men. Hypertension 1998; 31: 780-786.
3. Skoog I., Lernfelt B., Landahl S.: Fitteen-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
4. Elias M.E., Wolf P.A., D’Agostino R.B.: Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am. J. Epidemiol. 1993; 138: 353-364.
5. Tzourio C., Dufouil C., Ducimetiere P. et al.: Cognitive decline in individuals with high blood pressure. Neurology 1999; 53: 1948-1952.
6. Launer L.J., Masaki K., Petrovitch H. i wsp.: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu – Asia Aging Study. JAMA 2004; 292: 2237-2242.
7. Elias P.K., Elias M.F., Robbins M.A. et al.: Blood pressure-related cognitive decline: does age make a difference? Hypertension 2004; 44: 631-636.
8. Suhr J.A., Stewart J.C., France C.R.: The relationship between blood pressure and cognitive performance in the Third National Health and Nutrition Examination Survery (NHANES III). Psychosom. Med. 2004; 66: 291-297.
9. Kuo H.K., Yen C.J., Chang C.H. et al.: Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005; 4(6): 371-380.
10. Bellew K.M., Pigeon J.G., Stang P.E. et al.: Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Dis. Assoc. Disord. 2004; 18(4): 208-213.
11. Launer L.J., Masaki K., Petrovitch H. et al.: The association between midlife blood pressure levels and late-life cognitive function. JAMA 1995; 274: 1846-1851.
12. Launer L.J., Ross G.W., Petrovitch H. et al.: Midlife blood pressure levels and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2000; 21: 49-55.
13. Jennings J.R.: Autoregulation of blood pressure and thought: preliminary results of an application of brain amaging to psychosomatic medicine. Psychosom. Med. 2003; 65: 384-395.
14. Mulvany M.J.: Small aorty remodeling and significance in the development of hypertension. New Physiol. Sci. 2002; 17: 105-109.
15. Manolio T.A., Olson J., Longstreth W.T.: Nadciśnienie tętnicze a funkcje poznawcze: patofizjologiczny wpływ nadciśnienia tętniczego na mózg. Medycyna po Dyplomie 2004; 13(15): 88-98.
16. van Dijk W.J., Breteler M.M.B., Schmidt R. et al.; CASCADE Consortium: The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004; 44: 625-630.
17. Majeski E.I., Widener C.E., Basile J.: Hypertension and dementia: does blood pressure control favorably affect cognition? Curr. Hypertens. Rep. 2004; 6: 357-362.
18. Di Bari M., Pahor M., Franse L.V.: Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in elderly program (SHEP) trial. Am. J. Epidemiol. 2001; 153: 72-78.
19. Forette F., Seux M.I., Staessen J.A.: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch. Intern. Med. 2002; 162: 2046-2052.
20. Lithell H., Hansson L., Skoog I. et al.: The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 2004; 22: 1605-1612.
21. Lithell H., Hansson L., Skoog I.: The Study on COgnition and Prognosis in the Elderly (SCOPE); principal results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21: 875-886.
22. Feigin V., Ratnasabapathy Y., Anderson C.: Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J. Neurol. Sci. 2005; 229-230: 151-155.
23. McGuinness B., Todd S., Passmore P.: The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst. Rev. 2006; 2, CD004034.
24. Birkenhäger W.H., Staessen J.A.: Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog. Cardiovascular Dis. 2006; 49: 1-10.
25. Birns J., Morris R., Donaldson N. et al.: The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J. Hypertens. 2006; 24: 1907-1914.
26. Guo Z., Fratiglioni L., Zhu L. et al.: Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch. Neurol. 1999; 56: 991-996.
27. Hagstrom B., Mattsson B., Rost I.M. et al.: What happened to the prescriptions? A single, short, standardized telephone call may increase compliance. Fam. Pract. 2004; 21: 46-50.
28. Grodzicki T., Gryglewski R., Tomasik T. et al.: Zasady postępowania w nadciśnieniu tętniczym w wieku podeszłym. Wytyczne Kolegium Lekarzy Rodzinnych w Polsce, Polskiego Towarzystwa Nadciśnienia Tętniczego, Polskiego Towarzystwa Gerontologicznego. Gerontol. Pol. 2012; 20(4): 119-147.
29. Manconi E., Binaghi F., Pitzus F.: A double-blind clinical trial of vinpocetine in the treatment of cerebral insuficiency of vascular and degenerative origin. Curr. Ther. Res. 1986; 40: 702-712.
30. Reisberg B., Ferris S.H., Shulman E. et al.: Longitudinal course on normal ageing and progressive dementia of Alzheimer’s type: a prospective study of 106 subject over a 3,6 year mean interval. Prog. Neuro-Psychopharmacol. Psychiatry 1986; 10: 571-578.
31. Reisberg B., Ferris S.H., de Leon M.J. et al.: Stage specific behavioral cognitive, and in vivo changes in community residing subjects with age associated memory impairment and primary degenerative dementia of Alzheimer type. Drug Develop. Res. 1988; 15: 101-114.
32. Petersen R.C., Doody R., Kurz A. et al.: Current concepts in mild cognitive impairment. Arch. Neurol. 2001; 58: 1985-1992.
33. Petersen R.C., Smith G.E., Waring S.C. et al.: Mild cognitive impairment: clinical characterization an outcome. Arch. Neurol. 1999; 56: 303-308.
34. Winblad B., Palmer K., Kipivelto M. et al.: Mild cognitive impairment – beyond controversies, towards a consensus: report of International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004; 256: 240-246.
35. Mitchell A.J., Shiri Feshki M.: Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatr. Scand. 2009; 119: 252-265.
36. Krasuski J.S., Alexander G.E., Horwitz B.: Volumes of medial temporal lobe structures in patiens with Alzheimer’s disease and mild cognitive impairment. Biol. Psychiatry 1998; 43: 60-68.
37. Callahan M., Hendrie H.C., Tierny W.M.: Documentation and evaluation of cognitive impairment in elderly primary care patiens. Ann. Intern. Med. 1995; 122: 422-429.
38. Gabryelewicz T., Styczyńska M., Łuczywek E. et al.: The rate conversion of mild cognitive impairment to dementia: predictive role of depression. Int. J. Geriatr. Psychiatry 2007; 22: 563-567.
39. Jack C.R., Petersen R.C., Xu Y. Warring S.C. et al.: Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997; 49: 786-794.
40. Nicholson C.D.: Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990; 101: 147-159.
41. Bönöczk P., Gulyás B., Adam-Vizi V. et al.: Role of sodium chanel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 2000; 3: 245-254.
42. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. The Cochrane Database of Systematic Reviews 2003, Issue 1.
43. Jacobs J.D., Bernhard M.R., Delgado A. et al.: Screening for organic mental syndromes in the medically ill. Ann. Intern. Med. 1977; 86: 40-48.